Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women
This is a phase II study evaluating the efficacy and safety of the pre-operative use of letrozole plus PD 0332991 (combination therapy)
ER Positive, HER2 Negative Breast Cancer
DRUG: Letrozole, PD 0332991
Objective response rates, Every 4 weeks before surgery
Number of Participants with Adverse Events, Continuous during the study, up to 28 days after the last treatment
Pathologic response rates, At time of definitive surgery
This is a phase II study evaluating the efficacy and safety of the pre-operative use of letrozole plus PD 0332991 (combination therapy)